# An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

> **NCT00632736** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 419 (actual)

## Conditions studied

- Parkinson Disease
- Parkinson's Disease

## Interventions

- **DRUG:** Ropinirole XL (formerly CR)

## Key facts

- **NCT ID:** NCT00632736
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632736, "An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00632736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*